CD151 drives cancer progression depending on integrin α3β1 through EGFR signaling in non-small cell lung cancer
2021 · Journal of Experimental & Clinical Cancer Research · 95 citations
https://doi.org/10.1186/s13046-021-01998-4
J
Jieqi Zhou
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
15
Papers
323
Citations
8
h-index
8
i10-index
Jieqi Zhou is an academic researcher from Northern Jiangsu People's Hospital. The author has contributed to research in topics: RNA modifications and cancer & Energy, Environment, Economic Growth & Ubiquitin and proteasome pathways. The author has an h-index of 8, co-authored 13 publications.
Papers by this author
worksIntegrin α3/α6 and αV are implicated in ADAM15-activated FAK and EGFR signalling pathway individually and promote non-small-cell lung cancer progression
2022 · Cell Death and Disease · 72 citations
https://doi.org/10.1038/s41419-022-04928-0
EVI5 is an oncogene that regulates the proliferation and metastasis of NSCLC cells
2020 · Journal of Experimental & Clinical Cancer Research · 25 citations
https://doi.org/10.1186/s13046-020-01585-z
CPNE1 promotes non-small cell lung cancer progression by interacting with RACK1 via the MET signaling pathway
2022 · Cell Communication and Signaling · 24 citations
https://doi.org/10.1186/s12964-021-00818-8
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat